The role of gut hormones and the hypothalamus in appetite regulation.
暂无分享,去创建一个
K. Simpson | S. Bloom | J. Minnion | Stephen R Bloom | Keisuke Suzuki | Katherine A Simpson | James S Minnion | Joyceline C Shillito | J. Shillito | Keisuke Suzuki
[1] J Mayer,et al. Regulation of Food Intake and Obesity , 1967, Science.
[2] G. P. Smith,et al. Cholecystokinin decreases food intake in rats. , 1973, Journal of comparative and physiological psychology.
[3] B. Vialettes,et al. Low Plasma Levels of Pancreatic Polypeptide in Obesity , 1980, Diabetes.
[4] V. Mutt,et al. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides , 1980, Nature.
[5] S. Woods,et al. Regulation of food intake and body weight in insulin. , 1981, Diabetologia.
[6] S. Leibowitz,et al. Hypothalamic paraventricular nucleus lesions produce overeating and obesity in the rat , 1981, Physiology & Behavior.
[7] G. P. Smith,et al. C-terminal octapeptide of cholecystokinin decreases food intake in man. , 1981, The American journal of clinical nutrition.
[8] J. Crawley,et al. Rapid development of tolerance to the behavioural actions of cholecystokinin , 1983, Nature.
[9] S. Bloom,et al. Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. , 1983, The Journal of clinical endocrinology and metabolism.
[10] P. Schneider,et al. Suppression of weight gain by glucagon in obese Zucker rats. , 1984, Experimental and molecular pathology.
[11] P S Kalra,et al. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. , 1984, Endocrinology.
[12] S. Woods,et al. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. , 1984, The American journal of physiology.
[13] R. Jorde,et al. Fasting and postprandial plasma pancreatic polypeptide (PP) levels in obesity. , 1984, International journal of obesity.
[14] J M Polak,et al. Human distribution and release of a putative new gut hormone, peptide YY. , 1985, Gastroenterology.
[15] I. Goldfine,et al. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. , 1985, The Journal of clinical investigation.
[16] S. Leibowitz,et al. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion , 1985, Peptides.
[17] W. Pardridge,et al. Human Blood—Brain Barrier Insulin Receptor , 1985, Journal of neurochemistry.
[18] J. E. Morley,et al. Peptide YY (PYY), a poteny orexigenic agent , 1985, Brain Research.
[19] S. Leibowitz,et al. Neuropeptide Y chronically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity , 1986, Peptides.
[20] K. Pienta,et al. Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance. , 1988, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[21] K. Polonsky,et al. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. , 1988, The Journal of clinical investigation.
[22] Terry D. Lee,et al. A new molecular form of PYY: Structural characterization of human PYY(3–36) and PYY(1–36) , 1989, Peptides.
[23] D. Whitcomb,et al. Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. , 1990, The American journal of physiology.
[24] D. Porte,et al. Localization of insulin receptor mRNA in rat brain by in situ hybridization. , 1990, Endocrinology.
[25] J. Raufman,et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.
[26] P. Gross,et al. Circumventricular organ capillaries. , 1992, Progress in brain research.
[27] S. Woods,et al. Inhibition of hypothalamic neuropeptide Y gene expression by insulin. , 1992, Endocrinology.
[28] E. Theodorsson,et al. Plasma concentrations of regulatory peptides in obseity following modified sham feeding (MSF) and a liquid test meal , 1992, Regulatory Peptides.
[29] N. Geary,et al. Glucagon acts in the liver to control spontaneous meal size in rats. , 1993, The American journal of physiology.
[30] B. Gallwitz,et al. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.
[31] M. Maffei,et al. Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.
[32] J. Holst,et al. Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.
[33] Steven L. Cohen,et al. Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.
[34] S. Wank. Cholecystokinin receptors. , 1995, The American journal of physiology.
[35] M. Maffei,et al. Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.
[36] M. Apfelbaum,et al. Gastric distension, hunger and energy intake after balloon implantation in severe obesity. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[37] M. Pelleymounter,et al. Effects of the obese gene product on body weight regulation in ob/ob mice. , 1995, Science.
[38] D. Drucker,et al. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[39] P. Brubaker,et al. Proglucagon processing in islet and intestinal cell lines , 1996, Regulatory Peptides.
[40] R. Considine,et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.
[41] W. Banks,et al. Leptin enters the brain by a saturable system independent of insulin , 1996, Peptides.
[42] L. Tartaglia,et al. Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice , 1996, Cell.
[43] R. Cone,et al. Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice , 1997, Cell.
[44] J. Little,et al. Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary‐adrenal activity , 1997, Clinical endocrinology.
[45] D. Thompson,et al. Characterization of cholecystokininA and cholecystokininB receptors expressed by vagal afferent neurons , 1997, Neuroscience.
[46] T. Ogihara,et al. Tissue-Specific and Glucose-Dependent Expression of Receptor Genes for Glucagon and Glucagon-Like Peptide-1 (GLP-1) , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[47] D. Schoeller,et al. Entrainment of the diurnal rhythm of plasma leptin to meal timing. , 1997, The Journal of clinical investigation.
[48] R. Darnell,et al. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[49] G. Schwartz,et al. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. , 1997, The American journal of physiology.
[50] P. J. Larsen,et al. Hypothalamic CART is a new anorectic peptide regulated by leptin , 1998, Nature.
[51] G M Steil,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Diurnal and Ultradian Rhythmicity of Plasma Leptin: Effects of Gender and Adiposity* , 2022 .
[52] A. Kelley,et al. Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens. , 1998, The Journal of pharmacology and experimental therapeutics.
[53] O. Kolterman,et al. Pramlintide, a Synthetic Analog of Human Amylin, Improves the Metabolic Profile of Patients With Type 2 Diabetes Using Insulin , 1998, Diabetes Care.
[54] C. Plata-salamán,et al. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.
[55] S. Bloom,et al. A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. , 1998, Endocrinology.
[56] J. Rehfeld,et al. The new biology of gastrointestinal hormones. , 1998, Physiological reviews.
[57] M. Fujimiya,et al. Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice☆ , 1999, Peptides.
[58] M. Nakazato,et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.
[59] H. Herzog,et al. Regional distribution of Y‐receptor subtype mRNAs in rat brain , 1999, The European journal of neuroscience.
[60] G. Schwartz,et al. Gut vagal afferent lesions increase meal size but do not block gastric preload-induced feeding suppression. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.
[61] G. Colditz,et al. The disease burden associated with overweight and obesity. , 1999, JAMA.
[62] D. Drucker. Glucagon-like Peptide 2 , 1999, Trends in Endocrinology & Metabolism.
[63] M. Schwartz,et al. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. , 1999, Diabetes.
[64] G. Schwartz,et al. The role of gastrointestinal vagal afferents in the control of food intake: current prospects. , 2000, Nutrition.
[65] N. Morin,et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. , 2000, Endocrinology.
[66] S. Woods,et al. Central nervous system control of food intake , 2000, Nature.
[67] M. Tschöp,et al. Ghrelin induces adiposity in rodents , 2000, Nature.
[68] Min-Seon Kim,et al. Investigation of the melanocyte stimulating hormones on food intake Lack of evidence to support a role for the melanocortin-3-receptor , 2000, Brain Research.
[69] Yue Feng,et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass , 2000, Nature Genetics.
[70] 上野 尚彦. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice , 2000 .
[71] S. Woods,et al. Amylin: a novel action in the brain to reduce body weight. , 2000, Endocrinology.
[72] B. Wisse,et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. , 2001, Diabetes.
[73] D L Hay,et al. Oxyntomodulin inhibits food intake in the rat. , 2001, Endocrinology.
[74] R. Palmiter,et al. Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.
[75] M. Nakazato,et al. A role for ghrelin in the central regulation of feeding , 2001, Nature.
[76] B. Stoffel‐Wagner. Neurosteroid metabolism in the human brain. , 2001, European journal of endocrinology.
[77] A. Astrup,et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.
[78] G A Colditz,et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. , 2001, Archives of internal medicine.
[79] S. Bloom,et al. Printed in U.S.A. Copyright © 2001 by The Endocrine Society Evidence of an Orexigenic Role for Cocaine- and Amphetamine-Regulated Transcript after Administration into Discrete Hypothalamic Nuclei , 2022 .
[80] W. A. Banks,et al. Anorectic effects of circulating cytokines: role of the vascular blood-brain barrier. , 2001, Nutrition.
[81] M. Tschöp,et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. , 2001, European journal of endocrinology.
[82] N. Vrang,et al. Glucagon-like peptide containing pathways in the regulation of feeding behaviour , 2001, International Journal of Obesity.
[83] Y. Taché,et al. Peripheral ghrelin selectively increases Fos expression in neuropeptide Y – synthesizing neurons in mouse hypothalamic arcuate nucleus , 2002, Neuroscience Letters.
[84] E. Air,et al. Acute third ventricular administration of insulin decreases food intake in two paradigms , 2002, Pharmacology Biochemistry and Behavior.
[85] H. Grill,et al. The Neuroanatomical Axis for Control of Energy Balance , 2002, Frontiers in Neuroendocrinology.
[86] J. A. Fernández-Represa,et al. Peptide YY Secretion in Morbidly Obese Patients Before and After Vertical Banded Gastroplasty , 2002, Obesity surgery.
[87] Graham M Lord,et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. , 2002, The Journal of clinical investigation.
[88] Noboru Murakami,et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. , 2002, Gastroenterology.
[89] Zhaohui Feng,et al. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats , 2002, Nature Neuroscience.
[90] D. Thompson,et al. Expression of the leptin receptor in rat and human nodose ganglion neurones , 2002, Neuroscience.
[91] R. Brolin,et al. Bariatric surgery and long-term control of morbid obesity. , 2002, JAMA.
[92] C. Lawrence,et al. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. , 2002, Endocrinology.
[93] E. Air,et al. The Catabolic Action of Insulin in the Brain Is Mediated by Melanocortins , 2002, The Journal of Neuroscience.
[94] E. Dellinger,et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. , 2002, The New England journal of medicine.
[95] J. Wilding. Neuropeptides and appetite control , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[96] A. Geliebter,et al. Amylin, food intake, and obesity. , 2002, Obesity research.
[97] D. Keire,et al. Structure and receptor binding of PYY analogs , 2002, Peptides.
[98] Rachel L. Batterham,et al. Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.
[99] Mohammad A Ghatei,et al. Inhibition of food intake in obese subjects by peptide YY3-36. , 2003, The New England journal of medicine.
[100] Mohammad A Ghatei,et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.
[101] A. Sahu. Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance , 2003, Frontiers in Neuroendocrinology.
[102] David Grundy,et al. Localization of orexin-1 receptors to vagal afferent neurons in the rat and humans. , 2003, Gastroenterology.
[103] E. H. Goulding,et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor , 2003, Nature Neuroscience.
[104] G. Frost,et al. Pancreatic polypeptide reduces appetite and food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.
[105] J. Holst,et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.
[106] J. Egan,et al. GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells , 2003, Diabetes/metabolism research and reviews.
[107] M. Fujimiya,et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. , 2003, Gastroenterology.
[108] J. Holst,et al. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety , 2003, Regulatory Peptides.
[109] J. Holst,et al. On the Physiology of GIP and GLP-1 , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[110] D. Macneil,et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. , 2004, Endocrinology.
[111] J. Holst,et al. Glucagon‐like peptide‐2 inhibits antral emptying in man, but is not as potent as glucagon‐like peptide‐1 , 2004, Scandinavian journal of gastroenterology.
[112] D. Drucker,et al. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. , 2004, Gastroenterology.
[113] C. Deacon. Circulation and Degradation of GIP and GLP-1 , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[114] A. G. Roseberry,et al. Neuropeptide Y-Mediated Inhibition of Proopiomelanocortin Neurons in the Arcuate Nucleus Shows Enhanced Desensitization in ob/ob Mice , 2004, Neuron.
[115] D. Coleman. Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice , 1978, Diabetologia.
[116] Mohammad A Ghatei,et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. , 2004, Endocrinology.
[117] H. Herzog,et al. NPY and Y receptors: lessons from transgenic and knockout models , 2004, Neuropeptides.
[118] T. Kigoshi,et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells , 2004, Autonomic Neuroscience.
[119] H. Jang,et al. Peptide YY is secreted after oral glucose administration in a gender-specific manner. , 2005, The Journal of clinical endocrinology and metabolism.
[120] Stephen R. Bloom,et al. The inhibitory effects of peripheral administration of peptide YY3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway , 2005, Brain Research.
[121] Y. Tao. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity , 2005, Molecular and Cellular Endocrinology.
[122] D. Drucker,et al. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. , 2005, Endocrinology.
[123] S. Bloom,et al. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. , 2005, The Journal of clinical endocrinology and metabolism.
[124] Dennis D. Kim,et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.
[125] K. Toshinai,et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. , 2005, Endocrinology.
[126] T. Horvath,et al. Cannabinoids, opioids and eating behavior: The molecular face of hedonism? , 2006, Brain Research Reviews.
[127] G. Frost,et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial , 2006, International Journal of Obesity.
[128] G Hu,et al. Body mass index and the risk of Parkinson disease , 2006, Neurology.
[129] A. Klibanski,et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. , 2006, The Journal of clinical endocrinology and metabolism.
[130] S. O’Rahilly,et al. Genetics of obesity in humans. , 2006, Endocrine reviews.
[131] R. Cone,et al. Characterization of leptin-responsive neurons in the caudal brainstem. , 2006, Endocrinology.
[132] H. Raybould,et al. Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. , 2007, Endocrinology.
[133] K. Yaffe,et al. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. , 2007, Current Alzheimer research.
[134] C. Koebnick,et al. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. , 2007, The Journal of clinical endocrinology and metabolism.
[135] D. Cummings,et al. Gastrointestinal regulation of food intake. , 2007, The Journal of clinical investigation.
[136] J. Holst. The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.
[137] A. Forbes,et al. Review article: glucagon‐like peptide 2 – current applications and future directions , 2007, Alimentary pharmacology & therapeutics.
[138] S. Bloom,et al. Gut Hormones as Mediators of Appetite and Weight Loss After Roux-en-Y Gastric Bypass , 2007, Annals of surgery.
[139] M. Sena-Esteves,et al. Selective Deletion of Bdnf in the Ventromedial and Dorsomedial Hypothalamus of Adult Mice Results in Hyperphagic Behavior and Obesity , 2007, The Journal of Neuroscience.
[140] Intragastric balloon for obesity. , 2007, The Cochrane database of systematic reviews.
[141] D. Ashby,et al. Recent progress in PYY research—An update report for 8th NPY meeting , 2007, Peptides.
[142] Sandra Coulon,et al. Safety of the Ullorex® Oral Intragastric Balloon for the Treatment of Obesity , 2007, Journal of diabetes science and technology.
[143] T. Reinehr,et al. Amylin and Its Relation to Insulin and Lipids in Obese Children Before and After Weight Loss , 2007, Obesity.
[144] S. Swoap,et al. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.
[145] P. Baldock,et al. PYY transgenic mice are protected against diet-induced and genetic obesity , 2008, Neuropeptides.
[146] M. Inoue,et al. Overweight and obesity trends among Japanese adults: a 10-year follow-up of the JPHC Study , 2008, International Journal of Obesity.
[147] E. F. Bailey,et al. A tasty morsel: the role of the dorsal vagal complex in the regulation of food intake and swallowing. Focus on "BDNF/TrkB signaling interacts with GABAergic system to inhibit rhythmic swallowing in the rat," by Bariohay et al. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.
[148] Subhajyoti De,et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity , 2008, Nature Genetics.
[149] S. Woods,et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. , 2009, Nature chemical biology.
[150] J. Brüning,et al. Hormone and glucose signalling in POMC and AgRP neurons , 2009, The Journal of physiology.
[151] S. Bloom,et al. Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. , 2009, Endocrinology.
[152] J. Mindell,et al. Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012 , 2008, Journal of Epidemiology & Community Health.
[153] Michael E. Lassman,et al. Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice , 2009, Diabetes.
[154] F. Roux,et al. The relationship of obesity and obstructive sleep apnea. , 2009, Clinics in chest medicine.
[155] J. Rosenstock,et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.
[156] S. Bloom,et al. Obesity treatment: novel peripheral targets. , 2009, British journal of clinical pharmacology.
[157] M. Bessler,et al. Prospective Study of Gut Hormone and Metabolic Changes After Adjustable Gastric Banding and Roux-en-Y Gastric Bypass , 2009, International Journal of Obesity.
[158] C. la Vecchia,et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[159] S. Woods,et al. Meal-anticipatory glucagon-like peptide-1 secretion in rats. , 2010, Endocrinology.
[160] A. Buchman,et al. Teduglutide, a novel mucosally active analog of glucagon‐like peptide‐2 (GLP‐2) for the treatment of moderate to severe Crohn's disease , 2010, Inflammatory bowel diseases.
[161] H. Munzberg. Leptin-signaling pathways and leptin resistance. , 2010, Forum of nutrition.
[162] E. Diamandis,et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. , 2010, Endocrinology.
[163] J. Hebebrand,et al. From monogenic to polygenic obesity: recent advances , 2010, European Child & Adolescent Psychiatry.